NCT00458497

Brief Summary

This study is designed to assess the effects of socks and bedding materials on foot pain, the level of blood oxygen existing in the feet and quality of sleep in subjects who have chronic foot pain from either diabetic neuropathy or other conditions, e.g., peripheral arterial disease, regenerative joint disease). The three main hypotheses to be tested are: 1)compared to placebo socks, subjects wearing Holofiber socks experience reduction in foot pain, 2)compared to placebo bedding, subjects sleeping in beds lined with a Holofiber mattress pad experience improved quality of sleep and 3) compared to placebo socks, subjects who wear Holofiber socks will have increased blood oxygenation levels in their feet.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Apr 2007

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2007

Completed
8 days until next milestone

First Submitted

Initial submission to the registry

April 9, 2007

Completed
2 days until next milestone

First Posted

Study publicly available on registry

April 11, 2007

Completed
2.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2009

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2009

Completed
Last Updated

June 4, 2010

Status Verified

June 1, 2010

Enrollment Period

2.7 years

First QC Date

April 9, 2007

Last Update Submit

June 2, 2010

Conditions

Keywords

Holofiberchronic foot painsleep quality

Outcome Measures

Primary Outcomes (2)

  • Significant differences between the average scores from the two pre-randomization questionnaire sets and the two post-randomization questionnaire sets.

    four weeks

  • Oxygenation levels of blood in the feet will be compared between Holofiber and placebo socks at several time points using standard nonparametric t-test statistics.

    Baseline photos of feet without socks; immediately afer baseline photos, Holofiber sock placed on one foot, placebo sock placed on the other foot; second photos with socks one hour later; final photos with socks four hours later

Study Arms (2)

1

EXPERIMENTAL

Subjects will be given 3 pairs of socks (subjects with foot pain only) and bedding (mattress pad)fabricated from 1.8 dernier polyethylene terephthalate (PET) fabric to which Holofiber particles have been added during fiber manufacture.

Device: Holofiber fabric

2

PLACEBO COMPARATOR

Subjects will be given 3 pairs of socks (subjects with foot pain only) and bedding (mattress pad)fabricated from 1.8 dernier polyethylene terephthalate (PET) fabric.

Device: PET fabric

Interventions

Subjects will be given 3 pairs of socks (subjects with foot pain only) and bedding (mattress pad)fabricated from 1.8 dernier polyethylene terephthalate (PET) fabric to which Holofiber particles have been added during fiber manufacture.

1

Subjects will be given 3 pairs of socks (subjects with foot pain only) and bedding (mattress pad)fabricated from 1.8 dernier polyethylene terephthalate (PET)fabric.

2

Eligibility Criteria

Age21 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Presence of diabetic neuropathic pain with score of 3 or higher on the McGill Short Form Pain Survey
  • Presence of sensory neuropathy with monofilament (Semmes-Weinstein) testing, as defined as failure to sense the filament in 2 locations (out of six total) on a least one foot.
  • Previous diagnosis of diabetes (type II) as well as diabetic neuropathy by a physician
  • Age greater or equal to 21

You may not qualify if:

  • Presence of significant peripheral arterial disease in either lower extremity (abi greater than 0.9 bilaterally)
  • Skin ulceration on either foot or limb threat from infection or vascular disease at study enrollment
  • Inability to comply with study procedures or give informed consent
  • Women of child bearing potential
  • Spouse/partner is a women of child bearing potential and you share the same bed
  • Non-ambulatory status
  • Inability to comply with study restrictions on changing sleeping or pain medication
  • Severe psychiatric or medical disorder that would affect compliance
  • Known allergy to PET or Dacron
  • Chronic foot or angle pain with a score of 3 or higher on the McGill Short Form Pain Scale
  • Absence of sensory neuropathy with monofilament (Semmes-Weinstein) testing, as defined as ability to sense the filament in 6 locations (out of 6 total) on both feet
  • The presence of a condition that causes chronic foot pain such as arthritis, peripheral arterial disease, plantar fasciitis, or other conditions not related to diabetic neuropathy, previously diagnosed by a health care provider
  • Age greater to or equal to 21
  • Presence of significant peripheral arterial disease in either lower extremity (abi less than or equal to 0.5 in either extremity)
  • Skin ulceration on either foot or limb threat from infection or vascular disease at study enrollment
  • +8 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

VA Long Beach Healthcare System

Long Beach, California, 90822, United States

Location

Related Publications (1)

  • York RM, Gordon IL. Effect of optically modified polyethylene terephthalate fiber socks on chronic foot pain. BMC Complement Altern Med. 2009 Apr 22;9:10. doi: 10.1186/1472-6882-9-10.

Related Links

MeSH Terms

Conditions

Diabetic NeuropathiesArthritisPeripheral Arterial DiseaseFasciitis, PlantarSleep Initiation and Maintenance Disorders

Condition Hierarchy (Ancestors)

Peripheral Nervous System DiseasesNeuromuscular DiseasesNervous System DiseasesDiabetes ComplicationsDiabetes MellitusEndocrine System DiseasesJoint DiseasesMusculoskeletal DiseasesAtherosclerosisArteriosclerosisArterial Occlusive DiseasesVascular DiseasesCardiovascular DiseasesPeripheral Vascular DiseasesFasciitisFoot DiseasesSleep Disorders, IntrinsicDyssomniasSleep Wake DisordersMental Disorders

Study Officials

  • Ian Gordon, M.D., Ph.D.

    VA Long Beach Healthcare System

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

April 9, 2007

First Posted

April 11, 2007

Study Start

April 1, 2007

Primary Completion

December 1, 2009

Study Completion

December 1, 2009

Last Updated

June 4, 2010

Record last verified: 2010-06

Locations